Sotatercept administration in a young infant with severe pulmonary arterial hypertension: A case report - PubMed
3 days ago
- #Sotatercept
- #Pediatric Pulmonary Hypertension
- #Case Report
- Idiopathic pulmonary arterial hypertension (PAH) in infants is rare and life-threatening.
- 5-year survival in children is approximately 74% despite therapy advances.
- Sotatercept modulates TGF-beta signaling, improving vascular remodeling and vasodilation.
- FDA approved sotatercept for adults to improve exercise capacity and WHO functional class.
- First reported use of sotatercept in an infant with severe, refractory PAH showed clinical and echocardiographic improvement.